Pancreatic cancer blood test study pulled before it began
NCT ID NCT05188573
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study aimed to see if a simple blood test could spot early signs of pancreatic cancer in adults aged 50 and older who were recently diagnosed with type 2 diabetes. The plan was to enroll 10,000 participants and follow up with MRI scans for those with a positive test result. However, the study was withdrawn before any volunteers were enrolled, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- blood test for pancreatic cancer detection
- What this could lead to
- If validated, this test could help catch pancreatic cancer earlier in people with new-onset diabetes, potentially improving survival odds.
- What could go wrong
- The study was withdrawn before any participants enrolled, so no data was collected. The test's real-world accuracy and benefit remain unproven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Expected to start
-
Jun 2022
An estimate. Start dates often move.
- Expected to finish
-
May 2025
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
50 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * ≥50 years of age or older at the time of enrollment * Willing to provide and sign the informed consent form * Must have 2 occurrences from among the below parameters of diabetes mellitus (PDMs) in past 90 days measured in outpatient setting (not in urgent care, emergency room or while inpatient): * FBG ≥126mg/dl * HbA1c ≥ 6.5% * RBG ≥200mg/dl * 2-hour post-glucose ≥ 200mg/dl (OGTT) * Must have had glycemic parameter measured in 3-18 months prior to screening without meeting DM criteria * Must be willing to provide several tubes of blood without endangering health * No history of pancreatic cancer * No history of IPMNs, other neoplastic cysts and pancreatitis * No active cancers within the past 5 years (with the exception of non-melanoma skin cancers resolved/treated \> 1 year prior to enrollment and in situ carcinomas) Exclusion Criteria: * Prior DM diagnosis * Met criteria for DM ≥91 days prior to enrollment (patients with prior gestational diabetes that has resolved are NOT acceptable to enroll) * Carried a DM diagnosis or used anti-DM medications at a time greater than or equal to 91 days prior to enrollment * Any known pancreatic lesions * Received cancer treatment within the past 5 years (with the exception of treatment of non- melanoma skin cancer), carrying a current cancer diagnosis, and/or being investigated for suspicion of past cancer recurrence. * Current chronic or acute oral steroid use * History of intra-articular steroid injections (\<1 week) of the qualifying DM blood test (allowed exception: nasal, topical, oral budesonide) * Any surgery requiring general anesthesia within 2 months of collection * Local anesthetic (including dental novocaine) within 1 week of collection * History or presence of HIV/AIDs, Hepatitis A or E within the past five years, TB, any kind of prion disorder (e.g., CJD) * Blood transfusion within 1 month * Organ transplant recipient * Currently pregnant, or pregnancy within last 12 months * Receipt of systemic immunomodulation therapy within past 12 months * Significant medical condition that in the site investigator's opinion would compromise the subject's ability to tolerate study interventions
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for New-onset type II diabetes are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Bluestar Genomics, Inc.
San Diego, California, 92121, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a blood test before pancreatic surgery predict a dangerous leak?
- New chemo cocktail targets pancreatic cancer at every stage
- Bacteria-Based immunotherapy targets pancreatic tumors in first human test
- Can a new radiation machine cut breath holds for cancer patients?
- Two oral drugs join chemotherapy in a bid to shrink pancreatic tumors
- Nerve-Block procedure tested against severe pancreatic and stomach cancer pain